Results of the Phase III DASISION trial and the future of CML treatment
An unmet need: reducing early death in amyloidosis
MRD negativity and its role as a predictor for CLL patient responses
Diagnosis, classification and treatment of systemic mastocytosis
Novel therapies in myeloma: selinexor, venetoclax, among others
Heinz Ludwig et al.